Viewing Study NCT00773695


Ignite Creation Date: 2025-12-24 @ 1:14 PM
Ignite Modification Date: 2025-12-28 @ 8:44 PM
Study NCT ID: NCT00773695
Status: COMPLETED
Last Update Posted: 2023-01-09
First Post: 2008-10-15
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
Sponsor: Hoffmann-La Roche
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module